InspireMD (NYSE:NSPR) Coverage Initiated at

Investment analysts at assumed coverage on shares of InspireMD (NYSE:NSPRGet Rating) in a research note issued on Wednesday. The firm set a “sell” rating on the stock.

Separately, Alliance Global Partners decreased their target price on shares of InspireMD from $5.15 to $4.75 in a research note on Wednesday, May 17th.

InspireMD Trading Down 5.1 %

InspireMD stock opened at $1.67 on Wednesday. InspireMD has a 12 month low of $0.81 and a 12 month high of $2.40. The business’s 50 day simple moving average is $1.27 and its 200 day simple moving average is $1.17. The company has a market cap of $13.91 million, a price-to-earnings ratio of -0.73 and a beta of 0.88.

InspireMD (NYSE:NSPRGet Rating) last announced its earnings results on Thursday, March 30th. The company reported ($0.60) earnings per share (EPS) for the quarter. InspireMD had a negative return on equity of 93.16% and a negative net margin of 349.45%. The company had revenue of $1.03 million during the quarter.

Insider Activity at InspireMD

In other InspireMD news, Director Paul Stuka bought 175,000 shares of InspireMD stock in a transaction dated Friday, May 12th. The shares were purchased at an average cost of $1.63 per share, for a total transaction of $285,250.00. Following the acquisition, the director now directly owns 248,534 shares in the company, valued at approximately $405,110.42. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 9.82% of the stock is owned by corporate insiders.

About InspireMD

(Get Rating)

InspireMD, Inc is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions.

Further Reading

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with's FREE daily email newsletter.